scholarly journals The role of FDX1 in granulosa cell of Polycystic ovary syndrome (PCOS)

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Zhi Wang ◽  
Hui Dong ◽  
Li Yang ◽  
Ping Yi ◽  
Qing Wang ◽  
...  
Keyword(s):  
Granulosa Cell ◽  
Testosterone Propionate ◽  
Polycystic Ovary ◽  
Antral Follicle ◽  
Steroid Metabolism ◽  
Rt Pcr ◽  
Ovary Syndrome ◽  
Unique Identifier ◽  
And Control

Abstract Background To explore the development mechanism of PCOS and Transcriptomics was applied to seek the key gene. Methods Transcriptomics marked by UID (unique identifier) technique of granulosa cell in PCOS and control women was carried out and key gene was picked up. Then the key gene in granulosa cell was measured by RT-PCR. Two PCOS models modeling with Letrozole and Testosterone Propionate were implemented and the key gene in granulosa cell of ovary was measured by immunohistochemistry to verify the relation with PCOS. Results GO-enrich of transcriptomics concentrated in domain steroid metabolism and domain mitochondria. Different genes were sought from coexisting in both domain steroid metabolism and domain mitochondria. Finally, five different genes including CYP11A1、CYB5R1、STAR、FDX1 and AMACR were obtained. RT-PCR was implemented to furtherly verify the downregulating mRNA of FDX1 in PCOS, which showed the consistent outcome with the transcriptomics. Level of FDX1 protein in granulosa cell of antral follicle in two PCOS models was measured and decreased. Conclusions FDX1 was related with steroid metabolism and mitochondrial and may participate in the development of PCOS.

scholarly journals The Role of FDX1 in Granulosa Cell of Polycystic Ovary Syndrome (PCOS)

2021 ◽  
Author(s):  
zhi wang ◽  
Hui Dong ◽  
Li Yang ◽  
Ping Yi ◽  
Qing Wang ◽  
...  
Keyword(s):  
Granulosa Cell ◽  
Testosterone Propionate ◽  
Polycystic Ovary ◽  
Antral Follicle ◽  
Steroid Metabolism ◽  
Rt Pcr ◽  
Ovary Syndrome ◽  
Unique Identifier ◽  
And Control

Abstract Background: To explore the development mechanism of PCOS and Transcriptomics was applied to seek the key gene.Methods: Transcriptomics marked by UID (unique identifier) technique of granulosa cell in PCOS and control women was measured. RT-PCR was applied to verify the key gene. Two kinds of PCOS models modeling with Letrozole and Testosterone Propionate were applied to verify the key gene of granulosa cell in PCOS. Results: The outcome of GO-enrich of transcriptomics concentrated in steroid metabolism and mitochondria. The different genes were sought from coexisting in both steroid and mitochondria. Finally, five different genes including CYP11A1、CYB5R1、STAR、FDX1 and AMACR were obtained. RT-PCR was administrated to furtherly verify the downregulating FDX1 in PCOS, which showed the consistent outcome with the transcriptomics. FDX1 in granulosa cell of antral follicle in both PCOS model rats was measured and was lower than control rats, which was consistent in two kinds of PCOS models. Conclusion: FDX1 was related with steroid metabolism and mitochondrial and may participate in the development of PCOS.

scholarly journals BMP system expression in GCs from polycystic ovary syndrome women and the in vitro effects of BMP4, BMP6, and BMP7 on GC steroidogenesis

2013 ◽  
Vol 168 (3) ◽  
pp. 437-444 ◽  
Author(s):  
Mohamad Khalaf ◽  
Julia Morera ◽  
Antoine Bourret ◽  
Yves Reznik ◽  
Christine Denoual ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Bone Morphogenetic Proteins ◽  
Polycystic Ovary ◽  
Rt Pcr ◽  
Ovary Syndrome ◽  
Reproductive Process ◽  
In Vitro Effects ◽  
Predominant Expression

BackgroundThe bone morphogenetic proteins (BMPs) are growth factors involved in the folliculogenesis. Alteration in their expression may compromise the reproductive process in disease such as the polycystic ovary syndrome (PCOS). This study investigated the expression and role of granulosa cell (GC) BMP from normal cycling and PCOS women.Methods and resultsThis prospective study was performed in GCs obtained from 14 patients undergoing IVF: i) six women with normal ovulatory cycles and tubal or male infertility and ii) eight women with PCOS. BMP2, BMP4, BMP5, BMP6, BMP7, and BMP8A and their receptors BMPR1A, BMPR1B, and BMPR2 were identified by RT-PCR in GCs from normally cycling and PCOS women. BMP4, BMP6, and BMP7 expressions were confirmed by immunohistochemistry. Quantitative transcript analysis showed the predominant expression of BMP6. In GCs from PCOS women, an overexpression of BMP6 (P<0.01) and BMPR1A mRNA (P<0.05) was observed. GC culture experiments demonstrated that basal estradiol (E2) production was threefold higher but FSH-induced E2 increment was twofold lower in PCOS compared with controls. In PCOS, BMP6 and BMP7 exerted a stimulatory effect on basal E2 production while BMP4 and BMP6 inhibited FSH-induced E2 production. FSH receptor and aromatase expression were not different between both groups.ConclusionThe BMP system is expressed in human GCs from normal cycling and PCOS women. The BMP may be involved in reproductive abnormalities found in PCOS.

scholarly journals Anti-Müllerian Hormone in Pathogenesis, Diagnostic and Treatment of PCOS

2021 ◽  
Vol 22 (22) ◽  
pp. 12507
Author(s):  
Ewa Rudnicka ◽  
Michał Kunicki ◽  
Anna Calik-Ksepka ◽  
Katarzyna Suchta ◽  
Anna Duszewska ◽  
...  
Keyword(s):  
Ultrasound Examination ◽  
Current Knowledge ◽  
Polycystic Ovary ◽  
Antral Follicle ◽  
Antral Follicle Count ◽  
Ovary Syndrome ◽  
Antral Follicles ◽  
Ovulatory Dysfunction ◽  
Reproductive Aged Women

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among reproductive-aged women. It is characterized by chronic anovulation, hyperandrogenism, and the presence of polycystic ovary in ultrasound examination. PCOS is specified by an increased number of follicles at all growing stages, mainly seen in the preantral and small antral follicles and an increased serum level of Anti-Müllerian Hormone (AMH). Because of the strong correlation between circulating AMH levels and antral follicle count on ultrasound, Anti-Müllerian Hormone has been proposed as an alternative marker of ovulatory dysfunction in PCOS. However, the results from the current literature are not homogeneous, and the specific threshold of AMH in PCOS and PCOM is, therefore, very challenging. This review aims to update the current knowledge about AMH, the pathophysiology of AMH in the pathogenesis of PCOS, and the role of Anti-Müllerian Hormone in the treatment of this syndrome.

The role of vitamin D in metabolic and reproductive disturbances of polycystic ovary syndrome: A narrative mini-review

2020 ◽  
pp. 1-8
Author(s):  
Daniela Menichini ◽  
Gianpiero Forte ◽  
Beatrice Orrù ◽  
Giuseppe Gullo ◽  
Vittorio Unfer ◽  
...  
Keyword(s):  
Vitamin D ◽  
Polycystic Ovary Syndrome ◽  
Embryo Quality ◽  
Polycystic Ovary ◽  
Vitamin D Supplementation ◽  
Endometrial Receptivity ◽  
Metabolic Disturbances ◽  
Ovary Syndrome ◽  
Beneficial Role

Abstract. Vitamin D is a secosteroid hormone that plays a pivotal role in several metabolic and reproductive pathways in humans. Increasing evidence supports the role of vitamin D deficiency in metabolic disturbances and infertility in women with polycystic ovary syndrome (PCOS). Indeed, supplementation with vitamin D seems to have a beneficial role on insulin resistance and endometrial receptivity. On the other hand, exceedingly high levels of vitamin D appear to play a detrimental role on oocytes development and embryo quality. In the current review, we summarize the available evidence about the topic, aiming to suggest the best supplementation strategy in women with PCOS or, more generally, in those with metabolic disturbances and infertility. Based on the retrieved data, vitamin D seems to have a beneficial role on IR, insulin sensitivity and endometrial receptivity, but high levels and incorrect timing of administration seem to have a detrimental role on oocytes development and embryo quality. Therefore, we encourage a low dose supplementation (400–800 IU/day) particularly in vitamin D deficient women that present metabolic disturbances like PCOS. As far as the reproductive health, we advise vitamin D supplementation in selected populations, only during specific moments of the ovarian cycle, to support the luteal phase. However, ambiguities about dosage and timing of the supplementation still emerge from the clinical studies published to date and further studies are required.

Sign in / Sign up

Export Citation Format

Share Document